Every year, the American Society of Retina Specialists releases the results of its latest Preferences and Trends Survey at the annual meeting. This year, the survey highlighted some surprising differences between US and international retina specialists, including off-label medication use and what drives drug choices for patients, said Paul Hahn, MD, vitreoretinal surgeon at NJRetina.
Every year, the American Society of Retina Specialists releases the results of its latest Preferences and Trends Survey at the annual meeting. This year, the survey highlighted some surprising differences between US and international retina specialists, including off-label medication use and what drives drug choices for patients, said Paul Hahn, MD, vitreoretinal surgeon at NJRetina.
Transcript
Have there been any major surprises with the results of the American Society of Retina Specialists' Preferences and Trends Survey in recent years?
So the Preferences and Trends Survey is really designed to capture the preferences and trends of retina specialists year over year. And I think for the most part, we have a pretty good handle on the pulse of retina specialists. So, I can't say there have been any major surprises. There are a couple of things that are of interest, though, or perhaps are surprising.
For example, if we compare US versus international retina specialists’ responses, we'll see that the majority of US retina specialists use an off-label medication for treatment of retinal diseases as first line, whereas international retina specialists, at least surprising to me, tend to use less of that off-label medication. It's surprising because in the US, we do have FDA-approved options that are very effective,, if not more effective for those retinal diseases. The etiology for this is unclear. The reason for this is unclear. I would personally suspect that this reflects differences in health care systems.
So, in the US this year, our survey asked a separate question, which was the No. 1 reason why retina specialists choose the drugs that they choose, and 25% of responding retina specialists reported that the most important factor in selecting drugs were insurance mandates, beating out, for example, efficacy and safety, which at least to me, should be No. 1. Internationally, that number was only 12%. So again, this probably reflects differences in health care delivery systems, probably accounting for that disparity.
Another surprising response was that in the US, we saw a lot of retina specialists reporting difficulty in hiring staff—not surprising in itself. There's been a pervasive labor shortage, probably across all markets over the past year or so. But surprisingly, internationally, we didn't see that same difficulty. And I'm not sure if there's a selection bias or what the reason for that is, but another interesting difference.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More